Have you read this JDD consensus on advanced topical nonsteroidal therapies for atopic dermatitis?
Dive into this recent article from the March issue! A seven-dermatologist expert panel used a structured Delphi process to develop consensus statements on advanced topical nonsteroidal therapies in atopic dermatitis. The panel reviewed agents including topical ruxolitinib, tapinarof, roflumilast, crisaborole, tacrolimus, pimecrolimus, and delgocitinib and produced guidance intended to help clinicians weigh options for first-line therapy, proactive maintenance, combination regimens, safety, and long-term management.
Key points from the consensus include that these therapies were considered effective for reducing signs and symptoms and for improving patient reported outcomes such as pruritus and quality of life. The panel viewed nonsteroidal topicals as useful alternatives to prolonged topical corticosteroid exposure and suitable for sensitive or high impact sites. They also reported favorable tolerability and judged routine baseline or ongoing laboratory monitoring to be unnecessary in most cases. The statements were accompanied by SORT ratings and reached predefined agreement thresholds.
The report is expert consensus informed by literature review and not a substitute for randomized controlled data. Clinicians should review the full article for the specific statements, evidence grading, and practical considerations before changing practice or formulary decisions.
Read the full JDD article for the consensus statements, evidence summaries, and implementation points to inform clinical decision making in atopic dermatitis care.
J Drugs Dermatol. 2026;25(3). doi:10.36849/JDD.9806
Blog write-up assisted by AI
